Trial Profile
A Phase 1, Open-label Study of SNX-5422 Added to Ibrutinib in Chronic Lymphocytic Leukemia Subjects With Residual Disease
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; SNX 5422 (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors Esanex
- 21 Feb 2019 Status changed from active, no longer recruiting to discontinued.
- 16 Oct 2018 Planned primary completion date changed from 30 Sep 2018 to 16 Nov 2018.
- 26 Jul 2018 Planned primary completion date changed from 1 Jul 2018 to 30 Sep 2018.